Octreotide for advanced hepatocellular carcinoma：Meta-analysis of randomized controlled trials
10.3760/cma.j.issn.1673-4904.2010.16.010
- VernacularTitle:奥曲肽治疗晚期肝癌的Meta分析
- Author:
Weiping HUANG
;
Lijun YU
- Publication Type:Journal Article
- Keywords:
Octreotide;
Liver neoplasms;
Meta-analysis
- From:
Chinese Journal of Postgraduates of Medicine
2010;33(16):28-31
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the effect of octreotide on the survival of patients with advanced hepatocellular carcinoma(HCC).Methods Electronic databases searches were conducted.Meta-analysis of all randomized controlled trials (RCTs) comparing octreotide versus placebo or no treatment was performed.Results Five RCTs including 579 patients with HCC wers assessed.Meta-analysis of the five studies showed that octreotide had no significant effect on the 6,12 and 24 months survival rates of the patients(6months:OR=1.69,95%CI 0.89-3.21,P=0.11;12 months:OR=2.41,95%CI 0.83-6.93,P=0.10;24months:OR=0.58,95%CI 0.28-1.17,P=0.13).To perform the sensitivity analysis,the blank study,the trial detecting somatostatin receptor expression,the study with short survival or the two trials with short follow-up intervals were excluded,and the results also showed that the octreotide treatment had no significant effect on the 6 and 12 months survival rates.A sensitivity analysis based on two trials indicated that the 24months survival rate of the octreotide group was even lower than that of the control group(OR=0.51,95% CI0.27-0.98,P=0.04).Conclusions This Meta-analysis demonstrates that octreotide could not improve the survival of patients with advanced HCC.The administration of octreotide should not be recommended for the treatment of advaneed HCC.
